title: A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders.
abstract: This double-blind, placebo-controlled, 6-month follow-up treatment study investigated the efficacy of bromocriptine and nortriptyline in attenuating drinking behavior and psychiatric symptoms in 216 male alcoholic patients subtyped by comorbid psychiatric disorder(s). Three well-defined subtypes were examined: alcoholism only, alcoholism + affective/anxiety disorder, and alcoholism + antisocial personality disorder. It was hypothesized that both medications would relieve negative affective symptoms associated with alcohol use and would be particularly effective for the affective/anxiety subgroup. Contrary to our predictions, the only significant effects found were with the antisocial personality disorder patients who were receiving nortriptyline. One interpretation of the results was that nortriptyline may have reduced impulsive drinking in the antisocial personality disorder subgroup by actions on serotonergic neurotransmission.
authors.affiliation: Kansas City Veterans Administration Medical Center (151), Kansas City 64128, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Powell
authors.forename: J L
authors.initials: JL
authors.lastname: Campbell
authors.forename: J F
authors.initials: JF
authors.lastname: Landon
authors.forename: B I
authors.initials: BI
authors.lastname: Liskow
authors.forename: H M
authors.initials: HM
authors.lastname: Thomas
authors.forename: E J
authors.initials: EJ
authors.lastname: Nickel
authors.forename: T M
authors.initials: TM
authors.lastname: Dale
authors.forename: E C
authors.initials: EC
authors.lastname: Penick
authors.forename: S D
authors.initials: SD
authors.lastname: Samuelson
authors.forename: R B
authors.initials: RB
authors.lastname: Lacoursiere
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000145:classification / Q000523:psychology / Q000534:rehabilitation*; D000987:Antisocial Personality Disorder / Q000145:classification / Q000523:psychology / Q000534:rehabilitation; D001008:Anxiety Disorders / Q000145:classification / Q000523:psychology / Q000534:rehabilitation*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D003866:Depressive Disorder / Q000145:classification / Q000523:psychology / Q000534:rehabilitation*; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009661:Nortriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales; D012919:Social Behavior; D014728:Veterans / Q000523:psychology*
chemical_list: D001971:Bromocriptine; D009661:Nortriptyline